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Kudzu, a leguminous plant, has long been used in folk medicine. In particular, its ﬂowers are used in Japanese and Chinese
folk medicine for treating hangovers. We focused on the ﬂower of Kudzu (Puerariae thomsonii) ,a n dw ep r e v i o u s l yr e p o r t e dt h e
antiobesity eﬀect of Puerariae thomsonii ﬂower extract (PFE) in humans. In this study, we conducted an animal study to investi-
gate the eﬀect of PFE on visceral fat and hepatic lipid levels in mice with diet-induced obesity. In addition, we focused on gene
expressionproﬁlestoinvestigatetheantiobesitymechanismofPFE.MaleC57BL/6Jmicewerefedahigh-fatdiet(HFD)oranHFD
supplemented with 5% PFE for 14 days. PFE supplementation signiﬁcantly reduced body weight and white adipose tissue (WAT)
weight.Moreover,inthehistologicalanalysis,PFEsupplementationimprovedfattyliver.Hepaticreversetranscription-polymerase
chain reaction revealed that PFE supplementation downregulated acetyl-CoA carboxylase expression. For adipose tissue, the
expressions of hormone-sensitive lipase in WAT and uncoupling protein 1 in brown adipose tissue (BAT) were signiﬁcantly
upregulated.TheseresultssuggestthatPFEexertsantiobesityandantifattylivereﬀectsinhigh-fatdiet-inducedobesemicethrough
suppressing lipogenesis in the liver, stimulating lipolysis in WAT, and promoting thermogenesis in BAT.
1.Introduction
Puerariae ﬂower extract (PFE) is a crude extract from the
ﬂowers of Kudzu (Puerariae thomsonii). It contains approx-
imately 20 percent of isoﬂavones as the major ingredient. In
Japan,PFEisutilizedasnutritionalsupplementfortreatment
of hangovers and obesity.
Kudzu, a leguminous plant distributed in Japan, China,
and other areas, has long been used in folk medicine. In par-
ticular, Puerariae ﬂowers are used in Japanese and Chinese
folk medicine for treating hangovers [1–3]. Niiho et al. con-
ﬁrmed that the Puerariae lobata ﬂower exerts hepatoprotec-
tive eﬀects in individuals with liver injury induced by carbon
tetrachloride or a high-fat diet in animal studies [1, 3].
Recently,researchoftheeﬀectsofKudzuonlipidmetabolism
andobesitywasreported.Wangetal.conﬁrmedthatﬂavones
derivedfromRadixPuerariaeexertinhibitoryeﬀectsonbody
weight,abdominalfatcontent,andlipidlevelsintheliver[4].
In addition, we preliminarily investigated the eﬀect of PFE
on body weight in humans and found that PFE intake might
reduce body weight and abdominal fat content in mildly
obese subjects [5]. However, the antiobesity mechanism of
PFE is not known.
Obesity is a well-established risk factor for the develop-
ment of hypertension, diabetes, dyslipidemia, and cancers,
and it causes premature death [6]. An increase in visceral fat
is responsible for many of the metabolic abnormalities, such
asimpairedglucosetolerance,insulinresistance,andincreas-
ed very-low-density lipoprotein triglyceride (VLDL-TG)
levels, associated with abdominal obesity [7–9]. In addition,
it is reported that approximately 50% of cases of obesity
involving visceral fat accumulation are complicated by fatty
liver [10]. Fatty liver is a reversible condition in which trigly-
cerides accumulate in large vacuoles in hepatocytes. Severe
fatty liver is occasionally accompanied by inﬂammation, a
situation that is referred to as steatohepatitis. When inﬂam-
mation and steatohepatitis occur in people who do not drink
alcohol, the condition is called nonalcoholic steatohepatitis2 Evidence-Based Complementary and Alternative Medicine
(NASH), and it is known to correlate strongly with obesity
[11]. Sources of fatty acids stored in the liver are as follows:
59% of fatty acids are stored in white adipose tissue (WAT);
26% are produced by lipogenesis in hepatocytes; and 15%
are obtained from the diet [12]. Accordingly, it is considered
that both reducing WAT content and suppressing lipogenesis
in the liver are very important for controlling fatty liver.
WAT is a specialized connective tissue that functions as
the major storage site for fat in the form of triglycerides. For
use as energy, triglycerides are metabolized into fatty acids
and transported by the bloodstream to tissues such as the
liver and brown adipose tissue (BAT). Therefore, to prevent
obesity, it is important to stimulate lipolysis in WAT and
increase energy utilization in the liver and BAT.
Thus, in this study, we conducted an animal study to
investigate the eﬀect of PFE on visceral fat levels and hepatic
lipid accumulation in mice with diet-induced obesity. In
addition, we focused on the expression proﬁles of genes
relatedtobeta-oxidation andlipogenesisintheliver,lipolysis
in WAT, and thermogenesis in BAT to investigate the anti-
obesity mechanism of PFE.
2.MaterialsandMethods
2.1. Experimental Materials. PFE was purchased from Ohta’s
Isan Co. Ltd. (Ushiku city, Japan). PFE contains 7 isoﬂavones
(4 isoﬂavone glucosides: tectoridin (4.70%), tectorigenin 7-
O-xylosylglucoside (8.37%), 6-hydroxygenistein-6,7-diglu-
coside (3.38%), and glycitin (0.17%); 3 aglycones: tectori-
genin (0.83%), glycitein (0.10%), and genistein (0.06%)).
All isoﬂavone standard preparations were purchased from
Nagara Science Co., Ltd. (Gifu, Japan) and Tokiwa Phyto-
chemical Co., Ltd. (Chiba, Japan).
2.2. Experimental Animals. All procedures using animals
were performed in accordance with the Guidelines for the
Care and Use of Experimental Animals of the Japanese Asso-
ciation for Laboratory Animal Science and were approved by
the Ethical Committee of TOYO SHINYAKU Co., Ltd. Male
C57BL/6J mice were purchased from Charles River Labo-
ratories Japan Inc. (Yokohama, Japan) at the age of 6 weeks.
2.3. Test Environment. During the acclimation period, mice
were housed in polycarbonate animal cages (260 × 420 ×
180mm; CLEA Japan, Inc., Tokyo, Japan) in groups of 4 and
administered the MF diet (Oriental Yeast Co. Ltd., Tokyo,
Japan). During the test period, mice were housed in indi-
vidual stainless steel wire mesh cages (750 × 210 × 150mm;
Tokiwa, Tokyo, Japan) under a 12h light:dark cycle.
2.4. Experimental Design. A f t e ra c c l i m a t i o nf o r1w e e k ,
C57BL/6Jmicewereweighedandassignedtooneof2groups
so that the mean body weight of each group was uniform.
The control group was given a high-fat diet (HFD), and
the treatment group was given the HFD containing 5% PFE
(HFD + PFE) (Table 1). The animals were restricted-fed and
given water ad libitum for 14 days.
2.5. Body Weight and Food Intake. During the experiment,
the animals were weighed every 4 days. Food intake was
Table 1: Composition of the experimental diets.
Ingredient HFD HFD + PFE
Casein 20.0 20.0
Alpha-potato starch 28.2 23.2
Sucrose 13.0 13.0
Corn oil 20.0 20.0
Lard 10.0 10.0
Cellulose 4.0 4.0
Mineral mixture 3.5 3.5
Vitamin mixture 1.0 1.0
dl-Methionine 0.3 0.3
PFE 0.0 5.0
Total 100.0 100.0
Mineral mixture, AIN-76; Vitamin mixture, AIN-76
(g/100 g diet).
determineddailybydeterminingtheamountoffeedremain-
ingfromthepreviousday,andthemeandailyfoodintakefor
each animal was calculated.
2.6. Measurement of Fecal Lipids. All feces were collected
daily on days 11–14 after the start of the experiment. The
collected feces were dried for at least 3 days at 100◦Ca n d
weighed. After dry feces were crushed and homogenized,
fecallipidswereextractedusingtheFolchextractionprotocol
[13]. The total lipid content was determined by measuring
the total dry extract weight.
2.7. Measurement of Tissue Weight. Fourteen days after the
start of the experiment, mice were sacriﬁced, and then the
liver and interscapular brown, mesenteric, epididymal, and
retroperitoneal adipose tissues were removed. All samples
excluding BAT samples were weighed. Each sample was
cut into small pieces, dipped in RNAlater (Ambion, Tokyo,
Japan), and stored at −80◦C until RNA extraction. Another
pieceofeachliversamplewasstoredat −80◦Cforsubsequent
analysis.
2.8. Hepatic Histological Analysis. Oil Red-O staining was
performed in frozen liver sections to detect the presence of
fat. The degree of fatty liver was assessed by expert patholo-
gists. We entrusted all analyses to Narabyouri Research Co.,
Ltd. (Nara, Japan).
2.9. Real-Time QuantitativeReverse Transcription-Polymerase
Chain Reaction (RT-PCR). The total RNAs from the liver,
epididymal adipose tissue, and BAT were isolated using the
RNeasy Mini Kit (QIAGEN, Tokyo, Japan) according to the
manufacturer’s directions. Total RNA (1.0μg) was reverse-
transcribedintocDNAinareactionmixtureusingtheQuan-
tiTect Reverse Transcription kit (QIAGEN) according to the
manufacturer’s directions. The gene expression levels in the
liver, epididymal adipose tissue, and BAT were determined
using a real-time PCR system (MiniOpticon System; Bio-
Rad Laboratories, Inc., Tokyo, Japan), the QuantiTect SYBR
Green PCR kit (QIAGEN), and speciﬁc sets of primers
(Table 2). The relative gene expression level was calculatedEvidence-Based Complementary and Alternative Medicine 3
Table 2: Polymerase chain reaction primer sequences.
Gene name Function GenBank ID Direction Sequences
Fatty acid synthase (FAS) Forward TCCTGGGAGGAATGTAAACAGC
Lipogenesis NM 007988.3
Reverse CACAAATTCATTCACTGCAGCC
Acetyl-CoA carboxylase (ACC) Forward TGGATCCGCTTACAGAGACTTT
Lipogenesis NM 133904.2
Reverse GCCGGAGCATCTCATTCG
Carnitine palmitoyltransferase l (CPT1) Forward CTTCCAAGGCAGAAGAGTGG
Beta-oxidation NM 013495.2
Reverse GAACCTTGGCTGCGGTAAGAC
Medium-chain acyl dehydrogenase (MCAD) Forward TCGAAAGCGGCTCACAAGCAG
Beta-oxidation NM 007382.4
Reverse CACCGCAGCTTTCCGGAATGT
Acyl-CoA oxidase (ACO) Forward TCTTCTTGAGACAGGGCCCAG
Beta-oxidation AF006688.1
Reverse GTTCCGACTAGCCAGGCATG
Hormone-sensitive lipase (HSL) Forward CCTACTGCTGGGCTGTCAA
Lipolysis BC021642.1
Reverse CCATCTGGCACCCTCACT
Uncoupling protein 1 (UCP1) Forward CTGGGCTTAACGGGTCCTC
Thermogenesis NM 009463.2
Reverse CTGGGCTAGGTAGTGCCAGTG
PPARg coactivator alpha (PGCla) Forward TCGATGTGTCGCCTTCTTGC
Mitochondriogenesis BC066868.1
Reverse ACGAGAGCGCATCCTTTGG
GAPDH Forward ATGACATCAAGAAGGTGGTG
Housekeeping XM 001478412.1
Reverse CATACCAGGAAATGAGCTTG
with real-time PCR data relative to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH).
2.10. Statistical Analysis. Data were expressed as the mean ±
SEM. For comparisons between groups, analyses were per-
formed using unpaired t-tests on all test items. All statistical
analyses were performed using Statview ver. 5.0 (SAS Insti-
tute Japan Ltd., Tokyo, Japan), and signiﬁcance was set at
P<0.05.
3. Results
3.1. Body Weight and Food Intake. Table 3 shows the body
weight and amount of food intake 14 days after the start of
the experiment. There was no signiﬁcant diﬀerence between
the2groupsregardingfoodintake.Conversely,boththeﬁnal
body weight and body weight gain in the HFD + PFE group
were signiﬁcantly lower than those in the HFD group.
3.2. Liver and Adipose Tissue Weight. Table 3 shows the liver
weight and epididymal, mesenteric, and retroperitoneal adi-
pose tissue weights on day 14 after the start of the exper-
iment. There were no signiﬁcant diﬀerences between the 2
groups regarding liver weight and mesenteric adipose tissue
weight.However,epididymalandretroperitonealadiposetis-
sue weights in the HFD + PFE group were signiﬁcantly low-
er than those in the HFD group. These data indicate that PFE
reducesbodyweightbydecreasingfatweightinhigh-fatdiet-
induced obese mice.
3.3. Fecal Lipid Levels. There was no signiﬁcant diﬀerence
between the 2 groups regarding fecal lipid levels (Table 3). In
addition, food intake was not signiﬁcantly diﬀerent between
the 2 groups (Table 3), and thus, it was believed that energy
intake did not diﬀer substantially between the 2 groups.
3.4. Hepatic Histological Analysis. Table 4 and Figure 1 show
the hepatic histological analysis data on day 14 after the start
oftheexperiment.IntheHFD+PFEgroup,thedevelopment
of fatty liver was apparently suppressed.
3.5. Real-Time Quantitative RT-PCR. Table 5 shows the
eﬀect of PFE on mRNA expression in the liver, WAT, and
BAT. The expression of hepatic genes involved in lipogenesis
such as acetyl-CoA carboxylase (ACC) in the HFD + PFE
group was signiﬁcantly lower than that in the HFD group.
For WAT, hormone-sensitive lipase (HSL) was signiﬁcantly
upregulated in epididymal adipose tissue in the HFD + PFE
group. Similarly, uncoupling protein1 (UCP1) in BAT was4 Evidence-Based Complementary and Alternative Medicine
Table 3: Eﬀects of PFE on food intake, body weight, liver weight, adipose tissue weight, and fecal total lipids.
HFD HFD + PFE
Food intake, g/day 2.83 ±0.04 2.79 ±0.11
Final body weight, g 26.4 ±0.52 4 .9 ±0.3
∗
Body weight gain, g 2.8 ±0.31 .4 ±0.3
∗∗
Liver weight, g/100 g body weight 4.54 ±0.08 4.73 ±0.12
White adipose tissue weight
Epididymal, g/100 g body weight 3.22 ±0.18 2.49 ±0.14
∗∗
Mesenteric, g/100 g body weight 1.31 ±0.07 1.11 ±0.10
Retroperitoneal, g/100 g body weight 0.36 ±0.03 0.26 ± 0.02
∗
Fecal total Lipids, g/day 0.015 ±0.001 0.017 ±0.001
T h ed a t ar e p r e s e n tt h em e a n± SEM values (n = 8).
∗ and ∗∗ indicate signiﬁcantly diﬀerent at P <0.05, P <0.01, respectively.
Table 4: Results of hepatic histological analysis.
HFD HFD + PFE
Animal no. Animal no.
1 2 3 4 5 6 7 8 1234 5 678
Fatty liver +++ + ++ +++ +++ +++ + +++ −−−− − −−−
−:n oa b n o r m a l i t y ,±: minor, +: slight, ++: moderate, +++: severe.
Table 5: Eﬀect of PFE on mRNA levels in the liver, WAT, and BAT.
HFD HFD + PFE
Liver
FAS 1.00 ±0.28 0.58 ±0.10
ACC 1.00 ±0.11 0.70 ±0.06
∗
CPTl 1.00 ±0.14 1.21 ±0.14
MCAD 1.00 ±0.23 1.51 ±0.26
ACO 1.00 ±0.14 1.35 ±0.20
Epididymal adipose tissue
HSL 1.00 ±0.14 1.84 ±0.15
∗∗
Brown adipose tissue
UCPl 1.00 ±0.23 2.15 ±0.38
∗
PGCla 1.00 ±0.15 1.30 ±0.08
T h ed a t ar e p r e s e n tt h em e a n± SEM values (n = 8).
∗and ∗∗ indicate signiﬁcantly diﬀerent at P <0.05, P <0.01, respectively.
signiﬁcantly upregulated in the HFD + PFE group. The
expression of genes related to beta-oxidation, such as carni-
tine palmitoyltransferase1 (CPT1), medium-chain acyl-CoA
dehydrogenase (MCAD), and acyl-CoA oxidase (ACO), was
not signiﬁcantly diﬀerent between the 2 groups, although
theirexpressionswerehigherintheHFD+PFEgroup.These
results suggest that PFE has antiobesity eﬀects in high-fat
diet-induced obese mice through suppressing lipogenesis in
the liver, stimulating lipolysis in WAT, and promoting ther-
mogenesis in BAT.
4. Discussion
The Kudzu ﬂower is a rich source of isoﬂavones [14], and
soy isoﬂavones such as genistein and daidzein have been
reported to exert antiobesity eﬀects [15–17]. Recently, Kim
etal.reportedthatdaidzeinsupplementationpreventednon-
alcoholic fatty liver disease in an animal study [18], and thus,
it is believed that isoﬂavones are promising compounds for
preventing obesity and fatty liver disease.
In this study, PFE supplementation signiﬁcantly reduced
body weight, body weight gain, and WAT weight without
aﬀecting energy intake (i.e., food intake and fecal lipid con-
tent). It is known that obesity develops when energy intake
exceeds energy expenditure. Therefore, PFE was believ-
ed to exert antiobesity eﬀects by increasing energy expendi-
ture.
In our unpublished data, the isoﬂavone fraction from
Puerariae thomsonii stimulated body weight loss in mice. Soy
isoﬂavone is reported to exert antiobesity eﬀects through
suppressing lipogenesis in the liver by increasing protein
kinase A activity [18] and promoting lipolysis in WAT by
increasingcAMPlevels[19,20].Moreover,tectoridin,aniso-
ﬂavone characteristic of PFE, has been reported to modulate
the expression of beta-oxidation genes such as MCAD and
ACO in mice with ethanol-induced liver steatosis [21]. In
this study, PFE suppressed the expression of ACC and FAS,
which are rate-limiting enzymes in fatty acid biosynthesis, in
theliver.Inaddition,theexpressionofHSL,thepredominant
lipaseeﬀectorofcatecholamine-stimulatedlipolysis,wasalso
upregulated in WAT. Moreover, insigniﬁcant increases in the
expression of beta-oxidation genes such as CPT1, MCAD,
and ACO were observed (Table 5). These results are similar
totheantiobesityeﬀectsofisoﬂavones[18–20];therefore,the
active ingredient of PFE may be an isoﬂavone.
In addition, PFE supplementation signiﬁcantly upregu-
lated UCP1 expression in BAT. UCP1 is a key factor that
determines the level of thermogenesis in BAT, and perox-
isome proliferator-activated receptor gamma coactivator1a
(PGC1a) is known to control UCP1 expression and mito-
chondriogenesis. A number of studies using mice revealedEvidence-Based Complementary and Alternative Medicine 5
HFD HFD+PFE
Figure 1: Histological analysis of the liver (Oil Red-O staining). The liver was extracted 14 days after commencing the treatment. Oil Red-O
staining was performed in frozen liver sections to detect the presence of fat. Lipid droplets are stained red with Oil Red-O. The arrowhead
shows the lumen of a blood vessel. These images are representative of observations made on 8 mice per group. (Scale bar: 50μm).
that UCP1 in BAT controls body fat levels by promoting
energy expenditure [22–24]. Research about the eﬀects of
isoﬂavones on UCP1 expression in BAT is sparse; however,
it is generally known that cAMP promotes UCP1 expression
in BAT [25]. Therefore, PFE may promote UCP1 expression
by increasing cAMP levels in BAT as observed in WAT. These
results suggest that PFE aﬀects energy expenditure; however,
we have to validate this hypothesis by measuring oxygen
consumption.
NASH is associated with progressive liver disease, ﬁbro-
sis, and cirrhosis. Its pathogenesis is considered to include
2 steps. The ﬁrst step is the development of hepatic steatosis
duetotheaccumulationoffreefattyacidsintheliver,andthe
second step involves additional biochemical insults, includ-
ing oxidative stress, the upregulation of inﬂammatory medi-
ators, and dysregulated apoptosis [26, 27]. Currently, ther-
apeutic options for NASH are limited to medications that
reduce the risk factors. Therefore, suppressing hepatic lipid
accumulation, the ﬁrst step of the pathogenesis of NASH,
appears to be very important for preventing this hepatic
disorder. In this study, PFE supplementation suppressed the
development of fatty liver (Table 4). In addition, genes relat-
edtolipogenesisweresigniﬁcantlydownregulatedintheliver
by PFE ingestion (Table 5). Thus, PFE might be expected to
prevent NASH by suppressing hepatic lipid accumulation.
In fact, GOT, GPT, and gamma-GTP expressions were sig-
niﬁcantly reduced by PFE ingestion in our preliminary clini-
cal study [5]. This result supports the possibility that PFE
supplementation provides the dual eﬀects of preventing both
obesity and hepatic disorders.
5. Conclusion
Inthepresentstudy,theﬂowerextractofPuerariaethomsonii
has been demonstrated to possess antiobesity and antifatty
liver by in vivo assay. In addition, the ﬂower extract of
Puerariae thomsonii appears to exert these eﬀects through
suppressing lipogenesis in the liver and promoting lipolysis
in white adipose tissue and thermogenesis in brown adipose
tissue. In future research, we must clarify the detailed mech-
a n i s mo fP F Ea n di t se ﬀects on energy expenditure.
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